(Q36849148)

16 August 2017

1 reference

title

The role of TNFalpha in ulcerative colitis (English)

1 reference

16 August 2017

Bruce E Sands

1

1 reference

16 August 2017

Gilaad G Kaplan

series ordinal

2

1 reference

16 August 2017

publication date

13 June 2007

1 reference

The Journal of Clinical Pharmacology

16 August 2017

published in

1 reference

16 August 2017

volume

47

1 reference

16 August 2017

issue

8

1 reference

16 August 2017

page(s)

930-941

1 reference

Cyclosporine in inflammatory bowel disease

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0091270007301623

Revolution and evolution: 30 years of ileoanal pouch surgery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007301623

A comparison of hand-sewn versus stapled ileal pouch anal anastomosis (IPAA) following proctocolectomy: a meta-analysis of 4183 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007301623

Threefold increased risk of infertility: a meta-analysis of infertility after ileal pouch anal anastomosis in ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007301623

Results and complications after ileal pouch anal anastomosis: a meta-analysis of 43 observational studies comprising 9,317 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007301623

Inflammatory Bowel Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007301623

The role of Th1/Th2 polarization in mucosal immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007301623

Biologic therapy of inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007301623

Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007301623

Genetic and pathogenetic insights into inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007301623

The current future understanding of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007301623

Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007301623

Inflammatory bowel disease is associated with a TNF polymorphism that affects an interaction between the OCT1 and NF(-kappa)B transcription factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007301623

A new transcription factor that regulates TNF-alpha gene expression, LITAF, is increased in intestinal tissues from patients with CD and UC

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007301623

The use of the anti-tumour necrosis factor monoclonal antibody--infliximab--to treat ulcerative colitis: implications and trends beyond the available data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007301623

Recent developments in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007301623

Concordance of inflammatory bowel disease among Danish twins. Results of a nationwide study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007301623

New genes in inflammatory bowel disease: lessons for complex diseases?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007301623

Linkage of inflammatory bowel disease to human chromosome 6p

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007301623

Sex stratification of an inflammatory bowel disease genome search shows male-specific linkage to the HLA region of chromosome 6

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007301623

Genomewide search in Canadian families with inflammatory bowel disease reveals two novel susceptibility loci

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007301623

Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007301623

An allelic polymorphism within the human tumor necrosis factor alpha promoter region is strongly associated with HLA A1, B8, and DR3 alleles

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007301623

The contribution of human leucocyte antigen complex genes to disease phenotype in ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007301623

Crohn's disease-associated genetic marker is seen in medically unresponsive ulcerative colitis patients and may be associated with pouch-specific complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007301623

Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007301623

Tissue levels and post-prandial secretion of the intestinal growth factor, glucagon-like peptide-2, in controls and inflammatory bowel disease: comparison with peptide YY.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007301623

Production of IL-1beta, hydrogen peroxide, and nitric oxide by colonic mucosa decreases sigmoid smooth muscle contractility in ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007301623

Local release of human neutrophil lipocalin (HNL), IL-8, and TNF-alpha is decreased as response to topical prednisolone treatment in distal ulcerative colitis and proctitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007301623

RDP58, a locally active TNF inhibitor, is effective in the dextran sulphate mouse model of chronic colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007301623

Biologic therapy for inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007301623

Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007301623

Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007301623

Increased production of granulocyte-macrophage colony-stimulating factor in Crohn's disease--a possible target for infliximab treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007301623

Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007301623

Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007301623

Infliximab for acute, not steroid-refractory ulcerative colitis: a randomized pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007301623

Infliximab for induction and maintenance therapy for ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007301623

Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007301623

Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007301623

Infliximab for hospitalized patients with severe ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007301623

Infliximab as a novel therapy for pediatric ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007301623

Infliximab in pediatric ulcerative colitis: two-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007301623

Etiopathogenesis of inflammatory bowel disease: the importance of the pediatric perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007301623

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007301623

Infliximab maintenance therapy for fistulizing Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007301623

The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007301623

Risks and benefits of infliximab for the treatment of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007301623

Newer Therapies for Inflammatory Bowel Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007301623

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007301623

Treatment of ulcerative colitis in the cottontop tamarin using antibody to tumour necrosis factor alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007301623

A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007301623

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007301623

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007301623

Strategies for targeting tumour necrosis factor in IBD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007301623

Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007301623

Early studies on the safety and efficacy of thalidomide for symptomatic inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007301623

Successful treatment of idiopathic colitis and proctitis using thalidomide in persons infected with human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007301623

In vitro effects of oxpentifylline on inflammatory cytokine release in patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007301623

Combination therapy of pentoxifylline and TNFalpha monoclonal antibody in dextran sulphate-induced mouse colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007301623

Treatment with tumour necrosis factor inhibitor oxpentifylline does not improve corticosteroid dependent chronic active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007301623

Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007301623

Do patient preferences influence decisions on treatment for patients with steroid-refractory ulcerative colitis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007301623

Colonoscopy in octogenarians and older patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007301623

Anti-tumour necrosis factor alpha (infliximab) in the treatment of severe ulcerative colitis: result of an open study on 13 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007301623

Infliximab for treatment of steroid-refractory ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007301623

Infliximab for refractory ulcerative colitis or indeterminate colitis: an open-label multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007301623

Infliximab efficacy in pediatric ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007301623

21 January 2018

Identifiers

DOI

10.1177/0091270007301623

1 reference

16 August 2017

1 reference